NUTROPIN AQ NUSPIN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NUTROPIN AQ NUSPIN (NUTROPIN AQ NUSPIN).

How it works

Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK-STAT signaling pathway, leading to increased IGF-1 production and promotion of linear growth, protein synthesis, and lipolysis.

What the body does with it

Metabolism	Metabolized in the kidneys and liver via proteolysis; renal reabsorption and degradation contribute to clearance.
Excretion	Renal: >90% as intact peptide; minor biliary/fecal elimination (<5%)
Half-life	Terminal half-life: 3.9–4.3 hours (subcutaneous); supports daily dosing
Protein binding	~30–50% bound to growth hormone-binding protein (GHBP); low-affinity binding to other serum proteins
Volume of Distribution	0.7–1.0 L/kg; indicates distribution primarily into extracellular fluid and well-perfused tissues
Bioavailability	Subcutaneous: 70–90% (compared to intramuscular); subcutaneous route preferred for consistent absorption
Onset of Action	Subcutaneous: Serum IGF-1 elevation detectable within 3–6 hours; clinical effects (linear growth) apparent after 3–6 months of continuous therapy
Duration of Action	Subcutaneous: Growth-promoting effects sustained for 24 hours (once-daily dosing); serum levels return to baseline by 12–18 hours

Classification & Brands

Dosing & administration

Subcutaneous injection 0.16-0.24 mg/kg/week divided into 6-7 daily doses.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in patients with GFR <30 mL/min/1.73 m²; no specific dose adjustment guidelines for mild to moderate impairment.
Liver impairment	No specific dose adjustment guidelines for Child-Pugh A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to altered clearance.
Pediatric use	Growth hormone deficiency: 0.16-0.3 mg/kg/week subcutaneously divided into daily doses; Turner syndrome: up to 0.375 mg/kg/week; idiopathic short stature: up to 0.47 mg/kg/week; chronic renal insufficiency: 0.35 mg/kg/week.
Geriatric use	No specific dose adjustment; higher risk of adverse effects due to age-related decline in renal function and increased sensitivity; start at lowest effective dose.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NUTROPIN AQ NUSPIN (NUTROPIN AQ NUSPIN).

Breastfeeding	It is not known whether somatropin is excreted in human milk. Exogenous growth hormone is likely present in milk due to its systemic absorption. Caution should be exercised when administered to a nursing woman. M/P ratio not available.
Teratogenic Risk	No adequate and well-controlled studies in pregnant women. In animal studies, somatropin administered during gestation did not demonstrate teratogenic effects. However, growth hormone may have potential to increase maternal insulin-like growth factor 1 (IGF-1) levels, which could theoretically affect fetal growth. Risk cannot be ruled out; use only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Acute critical illness (e.g., open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure)","Active malignancy or neoplasms","Diabetic retinopathy","Hypersensitivity to somatropin or any excipients","Children with closed epiphyses","Prader-Willi syndrome with severe obesity or respiratory impairment"]

Clinical Precautions

Precautions

["Risk of secondary neoplasms in patients with prior radiation therapy","Increased risk of intracranial hypertension (pseudotumor cerebri)","Slipped capital femoral epiphysis in children","Progression of scoliosis","Pancreatitis","Fluid retention and edema","Hypersensitivity reactions","Increased mortality in critical illness","Requires monitoring of IGF-1 levels, glucose metabolism, and growth velocity"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NUTROPIN AQ NUSPIN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NUTROPIN AQ NUSPIN (NUTROPIN AQ NUSPIN).

How it works

What the body does with it

Metabolism	Metabolized in the kidneys and liver via proteolysis; renal reabsorption and degradation contribute to clearance.
Excretion	Renal: >90% as intact peptide; minor biliary/fecal elimination (<5%)
Half-life	Terminal half-life: 3.9–4.3 hours (subcutaneous); supports daily dosing
Protein binding	~30–50% bound to growth hormone-binding protein (GHBP); low-affinity binding to other serum proteins
Volume of Distribution	0.7–1.0 L/kg; indicates distribution primarily into extracellular fluid and well-perfused tissues
Bioavailability	Subcutaneous: 70–90% (compared to intramuscular); subcutaneous route preferred for consistent absorption
Onset of Action	Subcutaneous: Serum IGF-1 elevation detectable within 3–6 hours; clinical effects (linear growth) apparent after 3–6 months of continuous therapy
Duration of Action	Subcutaneous: Growth-promoting effects sustained for 24 hours (once-daily dosing); serum levels return to baseline by 12–18 hours

Classification & Brands

Dosing & administration

Subcutaneous injection 0.16-0.24 mg/kg/week divided into 6-7 daily doses.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in patients with GFR <30 mL/min/1.73 m²; no specific dose adjustment guidelines for mild to moderate impairment.
Liver impairment	No specific dose adjustment guidelines for Child-Pugh A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to altered clearance.
Pediatric use	Growth hormone deficiency: 0.16-0.3 mg/kg/week subcutaneously divided into daily doses; Turner syndrome: up to 0.375 mg/kg/week; idiopathic short stature: up to 0.47 mg/kg/week; chronic renal insufficiency: 0.35 mg/kg/week.
Geriatric use	No specific dose adjustment; higher risk of adverse effects due to age-related decline in renal function and increased sensitivity; start at lowest effective dose.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NUTROPIN AQ NUSPIN (NUTROPIN AQ NUSPIN).

Breastfeeding	It is not known whether somatropin is excreted in human milk. Exogenous growth hormone is likely present in milk due to its systemic absorption. Caution should be exercised when administered to a nursing woman. M/P ratio not available.
Teratogenic Risk	No adequate and well-controlled studies in pregnant women. In animal studies, somatropin administered during gestation did not demonstrate teratogenic effects. However, growth hormone may have potential to increase maternal insulin-like growth factor 1 (IGF-1) levels, which could theoretically affect fetal growth. Risk cannot be ruled out; use only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure.